Slynd kit is a prescription medicine containing Drospirenone, marketed by Exeltis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted from 15 to 30°C (59 to 86°F).
Key facts
- Active ingredient (INN)
- Drospirenone
- Brand
- Slynd
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- Exeltis
- Manufacturer
- Exeltis
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted from 15 to 30°C (59 to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G03AC10 Drospirenone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 June 2019
- Identifiers
- RxCUI 748797, 2171000, 2171001 +1DailyMed set ID db32bc55-f295-4d87-9dbb-0a2f45573dcfNDC 0642-7470Application NDA211367
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 24 tablet, film coated in 1 blister pack * 4 tablet, film coated in 1 blister pack | 0642-7470-01 | Exeltis | 1 September 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 23 May 2019 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Drospirenone is a prescription medicine indicated by females of reproductive potential to prevent pregnancy. It is available as kits. MedsAcross supplies Drospirenone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DrospirenoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SLYND prescribing information (Exeltis) · U.S. National Library of Medicine, DailyMed
Need Slynd kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.